Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.

Sirivichayakul, Chukiat; Barranco-Santana, Elizabeth A; Rivera, Inés Esquilín; Kilbury, Jennifer; Raanan, Marsha; Borkowski, Astrid; Papadimitriou, Athanasia; Wallace, Derek

Sirivichayakul, Chukiat; Barranco-Santana, Elizabeth A; Rivera, Inés Esquilín; Kilbury, Jennifer; Raanan, Marsha; Borkowski, Astrid; Papadimitriou, Athanasia; Wallace, Derek.

Afiliação

Sirivichayakul C; Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Barranco-Santana EA; CAIMED Center, Ponce School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico.
Rivera IE; Department of Pediatrics, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.
Kilbury J; Takeda Vaccines Inc., Cambridge, Massachusetts, USA.
Raanan M; Takeda Vaccines Inc., Cambridge, Massachusetts, USA.
Borkowski A; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Papadimitriou A; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Wallace D; Takeda Vaccines Inc., Cambridge, Massachusetts, USA.

J Infect Dis ; 225(9): 1513-1520, 2022 05 04.

Article em En | MEDLINE | ID: mdl-32658250

Assuntos

Vacinas contra Dengue; Vírus da Dengue; Dengue; Adulto; Anticorpos Neutralizantes; Anticorpos Antivirais; Criança; Humanos; Imunogenicidade da Vacina; Vacinas Atenuadas; Vacinas Combinadas

Palavras-chave

dengue; immunogenicity; persistence; safety; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Dengue / Vírus da Dengue / Vacinas contra Dengue Tipo de estudo: Clinical_trials Limite: Adult / Child / Humans Idioma: En Revista: J Infect Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google